chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Lymphadenopathy, Neck pain, Pain in extremity, Paraesthesia
Clinical narrative: Left arm pain/extending to left hand; Neck pain; Swollen lymph node in left neck area; Tingling in hand; Tired; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7533) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to contrast dye, latex and neoprene. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 06Mar2021 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 the patient experienced left arm pain, neck pain within 1 week of 2nd dose, swollen lymph node in left neck area, continuing pain in left arm, extending to left hand, tingling in hand, tired. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the events left arm pain/extending to left hand, neck pain, swollen lymph node in left neck area, tingling in hand and tired were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Nasopharyngitis, Nausea
Clinical narrative: Tiredness; Nausea; Light cold; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the left arm on 12Apr2021 at 12:00 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Apr2021 at 14:00, the patient experienced tiredness, nausea and light cold for 3 hours. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome for the events tiredness, nausea and cold were recovered on 12May2021.   No follow-up attempts are possible. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Pain, Pain in extremity
Clinical narrative: Severe pain; Soreness of both hands. It was difficult to hold onto a full coffee mug with both hands. My right hand still hurts if fingers are squished together, 4 weeks after 2nd dose of vaccine.; Aching of lower back; Aching of lower back, sacroiliac joints; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 12Mar2021 at 10:30 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included reitners syndrome, reactive arthritis, kidney disease and shellfish allergy. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021, the patient experienced severe pain, aching, soreness of both hands. It was difficult to hold onto a full coffee mug with both hands, aching of lower back and sacroiliac joints. These symptoms lasted 2 to 3 weeks. His right hand still hurts if fingers were squished together, 4 weeks after second dose of vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of these events and included treatment with acetaminophen (MANUFACTURER UNKNOWN) at bed time to afford sleeping. The clinical outcome of the events severe pain, aching, soreness of both hands, difficult to hold onto a full coffee mug with both hands, aching of lower back, sacroiliac joints and his right hand still hurts if fingers were squished together was recovered with lasting effects.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain
Clinical narrative: Headache; Overall soreness; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 10Apr2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 20Mar2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021, the patient experienced headache and overall soreness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache and overall soreness was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis, Pain in extremity
Clinical narrative: Woke up with bloody nose morning after vaccine; sore arm; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 12Apr2021 at 16:00 as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient did not have any known allergies. The patient did not take any other vaccines in four weeks. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Apr2021 at 09:30, the patient woke up with bloody nose, the morning after the vaccine and other symptom was sore arm. Therapeutic measures were not taken as a result of the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events- bloody nose and sore arm was recovered on 13Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Chills, Pain, Pyrexia
Clinical narrative: Strong body aches; Weakness; Chills; Fever over 101; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 11Apr2021 at 13:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was reported as none. The patient had no known allergies to any medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 21Mar2021 at 13:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 12Apr2021 at 02:00, the patient experienced strong body aches, weakness, chills and a fever over 101 (unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not as a result of the events.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events strong body aches, weakness, chills, fever over 101 was resolved on an unspecified date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Hyperhidrosis, Pyrexia
Clinical narrative: Fatigued; Lightheadedness; Sweating; Mild fever-like symptoms; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm left on 12Apr2021 at 09:45 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history included constipation predominant irritable bowel syndrome (IBS-C). Concomitant medication included PSYLLIUM fiber capsules started on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm left on 22Mar2021 at 11:00 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 04:00, the patient woke up with mild fever-like symptoms, sweating and lightheadedness. The patient fell back asleep at 05:00 and woke up at 07:30 without symptoms, just fatigued. Therapeutic measures were not taken as a result of these events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events lightheadedness, sweating, mild fever-like symptoms and fatigued was recovered on 13Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dizziness, Headache, Nausea
Clinical narrative: Sore arm; Sore neck; Light headed; Headache; Fever; Chills; Joint pain; Skin on fire; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 12Apr2021 at 12:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto hypothyroidism. Patient has known allergies to amoxicillin, nuts and seasonal allergy. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN), thyroid (ARMOUR THYROID), cetirizine hydrochloride (ZYRTEC), fluticasone propionate (FLONASE) and azelastine hydrochloride (ASTELIN) all for unspecified indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 19Mar2021 at 16:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 13:00 the patient experienced sore arm, sore neck, light headed, headache, fever, chills, joint pain, skin on fire and nausea. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, sore neck, light headed, headache, fever, chills, joint pain, skin on fire and nausea was resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Neck pain, Pain in extremity, Pyrexia, Skin burning sensation
Clinical narrative: Sore arm; Sore neck; Light headed; Headache; Fever; Chills; Joint pain; Skin on fire; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 12Apr2021 at 12:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto hypothyroidism. Patient has known allergies to amoxicillin, nuts and seasonal allergy. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN), thyroid (ARMOUR THYROID), cetirizine hydrochloride (ZYRTEC), fluticasone propionate (FLONASE) and azelastine hydrochloride (ASTELIN) all for unspecified indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 19Mar2021 at 16:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 13:00 the patient experienced sore arm, sore neck, light headed, headache, fever, chills, joint pain, skin on fire and nausea. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, sore neck, light headed, headache, fever, chills, joint pain, skin on fire and nausea was resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chest X-ray, Chills, Headache, Laboratory test, Nausea
Clinical narrative: Fever; Chills; Nausea; Headache; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 28Mar2021 at 13:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism (Hypothyroid), multiple sclerosis (MS) and Penicillin allergy. Concomitant medications included methylphenidate hydrochloride (RITALIN); baclofen (MANUFACTURER UNKNOWN); aciclovir (ACYCLOVIR); ergocalciferol (VITAMIN D2) and estradiol (MANUFACTURER UNKNOWN) all for an unknown indication, from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 28Mar2021 at 18:00 the patient experienced fever, chills, nausea, headache and body aches. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with (TYLENOL) and (MOTRIN) on an unknown date in 2021. On an unknown date in 2021, the patient underwent lab work, chest X-ray for the events and the results were unknown. The clinical outcome of the events fever, chills, nausea, headache and body aches were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Fever; Chills; Nausea; Headache; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 28Mar2021 at 13:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism (Hypothyroid), multiple sclerosis (MS) and Penicillin allergy. Concomitant medications included methylphenidate hydrochloride (RITALIN); baclofen (MANUFACTURER UNKNOWN); aciclovir (ACYCLOVIR); ergocalciferol (VITAMIN D2) and estradiol (MANUFACTURER UNKNOWN) all for an unknown indication, from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 28Mar2021 at 18:00 the patient experienced fever, chills, nausea, headache and body aches. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with (TYLENOL) and (MOTRIN) on an unknown date in 2021. On an unknown date in 2021, the patient underwent lab work, chest X-ray for the events and the results were unknown. The clinical outcome of the events fever, chills, nausea, headache and body aches were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Disturbance in attention, Dizziness, Headache, Pruritus
Clinical narrative: continued Dizziness; headache; itching; unable to concentrate or focus; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 06Apr2021(at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus. The patient had unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received medications within two weeks of vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021 at 20:00, the patient experienced continued dizziness, headache, itching, unable to concentrate or focus, it's been a week since vaccine and symptoms are better but still exist. It was unknown whether any therapeutic measures were taken as a result of the event. The event resulted in doctor or other healthcare professional office/clinic visit.  The clinical outcome of the events were continued dizziness, headache, itching, unable to concentrate or focus was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Vaccination site pain
Clinical narrative: Extreme fatigue; Body aches; Chills; Severe pain at injection site; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the right arm on 12Apr2021 at 13:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, lupus and sulfonamide allergy. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 13Apr2021 at 03:00 the patient experienced extreme fatigue, body aches, chills and severe pain at injection site. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events extreme fatigue, body aches, chills and severe pain at injection site were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: U
Vaccine: COVID19
Symptoms: Peripheral swelling, Rash
Clinical narrative: Severe swelling lower legs / feet (looked like balloons ans like ribber bands) around ankles. Started one day after vaccine lasted 6 days toe bruised from swelling; Rash several parts of body; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old of unknown gender patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 23Mar2021 at 17:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, diabetes, fibromyalgia, obesity, sicca syndrome, rheumatoid arthritis, chronic migraine and unspecified allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021 at 18:15 the patient experienced severe swelling lower legs/feet (looked like balloons and like ribber bands) around ankles which started one day after vaccine lasted 6 days and toe bruised from swelling. The patient also experienced rash on several parts of the body. Therapeutic measures were taken as a result of events and included treatment with muscle relaxers from severe cramping, off fleet c and Benedryl. The clinical outcome of the events swelling in leg was recovered on 30Mar2021 and rash were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Lymph node pain, Lymphadenopathy, Pain, Vaccination site pain
Clinical narrative: Swollen and tender lymph node in left armpit near injection site; Tender lymph node in left armpit; Fatigue; Full body aches; Pain at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 11Apr2021 at 17:00 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID -19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the patient experienced swollen and tender lymph node in left armpit near injection site, presenting 26 hours after injection of 2nd dose. The events did not present after 1st dose. The patient also experienced fatigue, full body aches and pain at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events swollen and tender lymph node in left armpit, fatigue, full body aches and pain at injection site were resolving at the time of this report.  No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Disorientation, Dizziness, Nausea, Pruritus
Clinical narrative: Very itchy; Disorientated; Dizzy; Nauseous; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 09Apr2021 at 15:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included peptic duodenitis, hip impingement, fructose sensitivity, gluten sensitivity, dairy sensitivity, sulfa allergy and latex allergy. Concomitant medications included esomeprazole (NEXIUM), tramadol (MANUFACTURER UNKNOWN) and acetaminophen (MANUFACTURER UNKNOWN) all taken for unknown indications and since unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 09Apr2021 at about 21:00, the patient got very itchy, quite disorientated, dizzy and nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events itchy, disoriented, dizziness and nauseous was resolved with sequelae on 10Apr2021 at 06:00.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: Itchy rash covering most of back. Started about 1 week post vaccination.; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 22Mar2021 at 09:00 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had no allergies to medications, food, or other products. The clinical course was reported as follows: on 29Mar2021, about one week post vaccination, the patient experienced itchy rash covering most of the back. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event itchy rash covering most of back was not recovered at this time of report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Aphthous ulcer, Ear discomfort, Nasal congestion, Rhinorrhoea
Clinical narrative: Sore cheeks; Runny nose; Stuffy nose; Ears feel full; This is a spontaneous report from a non-contactable consumer, the patient. A 39-year-old female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0162) via an unspecified route of administration on an unknown date (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune disease and allergic to sulfa. Concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID -19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date, the patient experienced sore cheeks, stuffy/runny nose and ears felt full. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events sore cheeks, stuffy/runny nose and ears felt full were resolved with sequelae on an unknown date at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dry mouth, Fatigue, Headache, Malaise
Clinical narrative: Fever; Chills; Aches; Fatigue; Headache; Malaise; Shaking; Dry mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration on an unknown date (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date the patient experienced fever, chills, aches, fatigue, headache, malaise, shaking and dry mouth. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, aches, fatigue, headache, malaise, shaking and dry mouth were unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Tremor
Clinical narrative: Fever; Chills; Aches; Fatigue; Headache; Malaise; Shaking; Dry mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration on an unknown date (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date the patient experienced fever, chills, aches, fatigue, headache, malaise, shaking and dry mouth. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, aches, fatigue, headache, malaise, shaking and dry mouth were unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper
Clinical narrative: Stomach pain; This is a spontaneous report from a non-contactable consumer, the patient. A 20-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021(at the age of 20-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 09Apr2021 the patient experienced stomach pain. Therapeutic measures were not taken as a result of the reported adverse event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event stomach pain was not recovered at the time of report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Pain in extremity, Paraesthesia, Vaccination site swelling
Clinical narrative: rundown, fatique; joint paint; tingling in legs and feet; foot pain; swelling in the injection site; arm pain; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in Apr2021(at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. It was not reported whether the patient received any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced rundown, fatigue (reported as fatique), joint paint, tingling in legs and feet, foot pain, swelling in the injection site, arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the events. The clinical outcome of the events rundown, fatigue (reported as fatique), joint paint, tingling in legs and feet, foot pain, swelling in the injection site, arm pain was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Dry mouth, Eyelid rash, Fatigue, Headache, Swelling face
Clinical narrative: Headache; Fatigue; Dry mouth; Blurry vision/ worse in one eye than the other; Face swelling; Red puncta rash on external & internal eye lids; Vomiting; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL9264) via an unspecified route of administration in the right arm on 08Apr2021 at 08:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included allergy to cephalosporins. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included daily intake of multivitamin (MANUFACTURER UNKNOWN) and biotin (MANUFACTURER UNKNOWN); both for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6204) via an unspecified route of administration in the right arm on 16Mar2021 at 08:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 08Apr2021 at 09:30, the patient experienced headache, fatigue, dry mouth for 48 hours, blurry vision for 1 hour (worse in one eye than the other), face swelling for 24 hours, red puncta rash on external and internal eye lids for 48 hours (may be due to vomiting). Since the vaccination, the patient had not been tested for COVID-19. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event blurry vision was resolved on 08Apr2021 at 10:30. The clinical outcome of the event swelling face was resolved on 09Apr2021 at 09:30. The clinical outcome of the events headache, fatigue, dry mouth and red puncta rash on external and internal eye lids was resolved on 10Apr2021 at 09:30. The clinical outcome of the event vomiting was resolved on an unspecified date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred, Vomiting
Clinical narrative: Headache; Fatigue; Dry mouth; Blurry vision/ worse in one eye than the other; Face swelling; Red puncta rash on external & internal eye lids; Vomiting; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL9264) via an unspecified route of administration in the right arm on 08Apr2021 at 08:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included allergy to cephalosporins. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included daily intake of multivitamin (MANUFACTURER UNKNOWN) and biotin (MANUFACTURER UNKNOWN); both for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6204) via an unspecified route of administration in the right arm on 16Mar2021 at 08:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 08Apr2021 at 09:30, the patient experienced headache, fatigue, dry mouth for 48 hours, blurry vision for 1 hour (worse in one eye than the other), face swelling for 24 hours, red puncta rash on external and internal eye lids for 48 hours (may be due to vomiting). Since the vaccination, the patient had not been tested for COVID-19. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event blurry vision was resolved on 08Apr2021 at 10:30. The clinical outcome of the event swelling face was resolved on 09Apr2021 at 09:30. The clinical outcome of the events headache, fatigue, dry mouth and red puncta rash on external and internal eye lids was resolved on 10Apr2021 at 09:30. The clinical outcome of the event vomiting was resolved on an unspecified date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Gradually worsening tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm left on 07Apr2021 at 19:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), tadalafil (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), aluminium hydroxide, magnesium hydroxide (MAGNESIUM), colecalciferol (VITAMIN D3) and ascorbic acid (VITAMIN C) for unknown indication from an unknown date. The patient previously received amoxillin (MANUFACTURER UNKNOWN) and bactrim (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 12:00, the patient experienced gradually worsening tinnitus. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event worsening tinnitus was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Rash erythematous, Rash papular
Clinical narrative: Raised and red body rash on neck, torso, back, and chest; Raised and red body rash on neck, torso, back, and chest; headache; nausea; major fatigue; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 13Apr2021 at 15:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included hodgkin's lymphoma in 2016 and unknown if ongoing. The patient had no known allergies to medications, food, or other products. Concomitant medications included colecalciferol (VITAMIN D3), ascorbic acid (VITAMIN C), cyanocobalamin (VITAMIN B12) and fluoxetine hydrochloride (PROZAC); all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 23Mar2021 at 15:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 07:00, about 36 hours after injection, the patient experienced raised and red body rash on neck, torso, back, and chest and also had a headache, nausea and major fatigue which subsided after 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the event raised and red body rash on neck, torso, back, and chest was not recovered while the events headache, nausea and major fatigue were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Mass
Clinical narrative: a tender lump above collarbone on left side; swollen lymph node(s) near the collar bone; a tender lump above collarbone on left side; After examining the site of the lump, it appeared to be swollen when compared to my collarbone on the right side.; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8729) via an unspecified route of administration in the left arm on 09Apr2021 at 13:15 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL), escitalopram oxalate (LEXAPRO), cetirizine hydrochloride (ZYRTEC), vitamin b12 nos (MANUFACTURER UNKNOWN) and vitamin d nos (VITAMIN D), all from unknown  dates and for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 18:00 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 08:00, 2 days after receiving the second dose of vaccine, the patient experienced a tender lump above the collarbone on the left side, the lump was not immediately visible, but the patient could feel it with her fingers and move it around. After examining the site of the lump, it appeared to be swollen when compared to her collarbone on the right side. The lump on the left side was the same side where patient received the vaccine.  After researched by the patient, it appeared that the tender lump might be a swollen lymph node(s) near her collar bone related to the Pfizer vaccine.  It had been present for 5 days, but appeared to be reducing in size and sensitivity as time went on. The patient contacted her primary care provider who had instructed her to monitor the lump and follow up in person after a few weeks if it had not subsided. The patient did not know if that was an adverse event, but wanted to report the symptoms what she was experiencing and submitted a report. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events tender lump above collarbone on left side, swollen lump and swollen lymph node(s) near the collarbone was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.